Investment Update - Paraytec

21 May 2026

Truetide plc

("Truetide", the "Company" or the "Group")

Investment update - Paraytec Advances CX300 Programme

Truetide plc (AIM: TRUE) announces that its 100%-owned investee company, Paraytec Limited ("Paraytec"), has completed the proof-of-concept phase of the alpha-synuclein assay development programme announced on 14 January 2026. The CX300 platform successfully demonstrated its ability to measure the aggregation kinetics of recombinant α-synuclein in the presence of oligomer-containing preparations.

This represents a significant step towards a potential high-value clinical screening tool for Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA), with the additional potential for monitoring of patient progress.

Alongside the aggregation assay, Paraytec has established a panel of recombinant α-synuclein variants - including the disease-associated A30P and A53T familial Parkinson's mutations and a fluorescently-taggable construct - which the Directors of Paraytec believe creates a compelling platform for comparative strain analysis and discrimination between distinct synucleinopathies.

Following the success of this preliminary project, Paraytec is considering a pilot study to assess rapid (<24-hour) detection of pathological α-synuclein seeding activity in biological samples and capability for detection in clinical samples.

Key Highlights

• Leverages CX300's real-time fluorescence particle counting to deliver rapid, reproducible aggregation readouts with potential workflow and speed advantages over existing RT-QuIC-based approaches; head-to-head comparison with established platforms will form part of the pilot programme.

• Proprietary panel of recombinant α-synuclein variants, including A30P, A53T and a site-specifically labelable construct, positions the platform for comparative strain analysis - a capability the Directors believe could support differential diagnosis between PD, DLB and MSA.

• A successful assay would address the major unmet need for scalable early detection of biomarkers in a neurological diagnostics market projected to reach US$9.2 billion by 2030 (CAGR >10%)*.

• Multiple potential commercial pathways: near-term research-use-only (RUO) instrument and assay kits; pharma partnership opportunities addressing the drug discovery market for anti-aggregation therapeutics; longer-term LDT/IVD clinical diagnostic tests; intellectual property position across assay format, variant panel and oligomer enrichment methodology will all be actively evaluated.

• Builds on collaboration with Professor Oliver Bandmann and the Sheffield Institute for Translational Neuroscience (SiTRAN).

Clinical and commercial rationale

Synucleinopathies represent one of the largest underserved diagnostic markets in neurology, with Parkinson's disease alone affecting an estimated 10 million people globally. Current diagnosis relies on phenotypic assessment and imaging, both of which typically detect disease only after substantial neurodegeneration.

Trevor Brown, CEO of Truetide, commented: "This pilot moves our CX300 platform into the high-value clinical screening arena. We see substantial commercial potential in delivering a rapid, accurate and preferably blood-based test for one of medicine's largest unmet needs. The Board of Paraytec is evaluating options for how best to advance this work and we will update Truetide shareholders as appropriate."

*https://www.marketsandmarkets.com/Market-Reports/neurological-biomarkers-market-153432005.html

For further information: